Philippines ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

Philippines Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Philippines Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $65 Mn in 2022 and is projected to reach $120 Mn in 2030, exhibiting a CAGR of 8% during the forecast period. The Philippines national budget for 2023 is $96 Bn or 22.2% of GDP. The majority of this, or 66.4%, is allocated to national government organizations. (NGAs). Social Services will account for $38 Bn, or 39.2%, of the planned National Budget of which $5.63 Bn will go to healthcare services. Hospital treatments will cost $0.22 Bn. Health insurance services account for $0.24 Bn. Services for public health receive $0.093 Bn.

One of the most prevalent childhood mental illnesses, Attention Deficit Hyperactivity Disorder (ADHD) is thought to impact 3 to 5 % of Filipinos between the ages of 0 and 14 years. People who have ADHD are afflicted with a condition that is defined by inappropriately high levels of impulsivity, hyperactivity, or inability to focus. Symptoms are frequently severe enough to impair social and scholastic performance. The origin of ADHD is still a mystery. The bulk of researchers, however, propose a neurological basis. Chemicals that communicate with the brain malfunction in children with ADHD. ADHD may be accompanied by a decrease in activity in the regions of the brain that regulate attention and degree of activity. Further research has shown that ADHD is inherited, which is why it often runs in families. Male and female relatives of children with ADHD are more prone to have the condition than the general population.

Stimulants and non-stimulants are the two primary types of medications used to treat ADHD in the Philippines. Antidepressants are also utilized occasionally. The most popular form of therapy for kids and teenagers is stimulants. This kind of medication is typically the first one a doctor will attempt. Stimulants have a lengthy history of use and are thoroughly studied. They support the brain's ability to regulate behavior, focus, and impulses. Several stimulants are Amphetamine (Adzenys XR-ODT), Amphetamine/dextroamphetamine (Adderall, Adderall XR), Dexmethylphenidate (Focalin, Focalin XR), Dextroamphetamine (Dexedrine), Lisdexamfetamine (Vyvanse), Methylphenidate (Concerta, Daytrana, Metadate, Methylin, Ritalin, Quillivant XR). The testing of non-stimulants is less extensive. They function differently than stimulants, but they can aid in impulse control and focus. Atomoxetine (Strattera), Clonidine ER (Kapvay), Guanfacine ER (Intuniv), and Viloxazine (Qelbree) are some of the non-stimulants used in the treatment of ADHD in the Philippines.

Market Dynamics

Market Growth Drivers

More patients with ADHD are likely to be diagnosed and seek treatment as awareness of the disorder rises in the Philippines. This is anticipated to increase demand for ADHD treatments and drugs. The main factors influencing the growth of the Philippines ADHD therapeutics market are the measures taken by the government to raise awareness of the condition, its treatment, and funding for the drugs for a cure. (ADHD). For example, The National Council on Disability Affairs (NCDA) leads National Attention Deficit Hyperactivity Disorder (ADHD) celebration on October 16-22 – “Declaring Every Third Week of October and Every Year Thereafter as the “National Attention Deficit Hyperactivity Disorder” directing ADHD Society Philippines to spearhead the celebration in partnership with various government and non-government organizations and Persons with Disability Affairs Offices of the local government units.

Market Restraints

Despite increased awareness of the disorder, there is still a sizable quantity of stigma in the Philippines. This may limit the development of the market by making it challenging for people with ADHD to get diagnosed and receive treatment. To treat the symptoms of ADHD, some people may opt to use non-prescription options like dietary supplements. This might reduce the desire for prescribed ADHD treatments and medications, which might reduce the Philippines ADHD therapeutics market expansion.

Competitive Landscape

Key Players

• Altomed Pharmaceutical (PHL)
• Zuellig Pharma (PHL)
• Jvzea Pharmaceuticals (PHL)
• Vizcarra Pharmaceutical (PHL)
• Farmacia Medica (PHL)
• Phil Pharmawealth (PHL)
• Eli Lily
• Pfizer
• Johnson & Johnson
• Lupin

Healthcare Policies and Regulatory Landscape

The Philippines' Food and Medication Administration (FDA) oversees medication regulation. In the Philippines, the FDA is in charge of ensuring the safety, efficacy, and quality of pharmaceuticals, medical devices, and food items. The FDA is an organization that reports to the Department of Health (DOH) and is in charge of policing and observing the production, distribution, and selling of pharmaceuticals and other goods intended for human consumption. The FDA also monitors drugs and other products after they have been introduced to the market to make sure they continue to satisfy safety and efficacy requirements. The FDA is responsible for overseeing the approval of food items, cosmetics, and medical devices in addition to drugs. Manufacturers, importers, and distributors of these goods must obtain licenses from the FDA, which also carries out inspections to verify that rules are being followed.